Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 22, 2025 Filed Apr 22, 2025 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-012436 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2025 Filed Apr 22, 2025 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $38.11 | $76,220.00 |
DisclosureSEC source: 0001127602-25-012436 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,255 Read SEC document |
| April 22, 2025 Filed Apr 22, 2025 20:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-012436 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 22:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-011829 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 22:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $36.18 | $72,360.00 |
DisclosureSEC source: 0001127602-25-011829 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,255 Read SEC document |
| April 08, 2025 Filed Apr 8, 2025 22:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-011829 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 22:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-010043 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,255 F1 · kind: bona fide third party donation. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 20:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-009780 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 20:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $43.58 | $87,160.00 |
DisclosureSEC source: 0001127602-25-009780 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,455 Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 20:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-009780 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 00:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,389 | $44.38 | $194,783.82 |
DisclosureSEC source: 0001127602-25-009711 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,005 F1 · kind: Sell to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 58,465 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009760 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,465 Underlying: Common Stock · 58,465 shares Expires 2035-03-13 F3 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Dr. Malik's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 2,293 | $0.00 Strike: $44.36 | $0.00 |
DisclosureSEC source: 0001127602-25-009760 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,293 Underlying: Common Stock · 2,293 shares Expires 2035-03-13 F2 · kind: Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Dr. Malik's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 39,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009760 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,844 F1 · kind: Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Dr. Malik's continued employment with the company on the scheduled vesting date. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 01:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 8,228 | $43.27 | $356,025.56 |
DisclosureSEC source: 0001127602-25-008791 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,394 F1 · kind: Sale to cover transaction in connection with the vesting of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-007915 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $42.50 | $85,000.00 |
DisclosureSEC source: 0001127602-25-007915 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 21:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-007915 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:39 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,449 | $42.88 | $105,013.12 |
DisclosureSEC source: 0001127602-25-008321 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,622 F1 · kind: Sale to cover transaction in relation to the vesting of restricted stock units. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-005237 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $45.98 | $91,960.00 |
DisclosureSEC source: 0001127602-25-005237 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| February 18, 2025 Filed Feb 18, 2025 21:32 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-005237 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-002944 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $48.06 | $96,120.00 |
DisclosureSEC source: 0001127602-25-002944 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 21:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-002944 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-001636 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $45.92 | $91,840.00 |
DisclosureSEC source: 0001127602-25-001636 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| January 21, 2025 Filed Jan 21, 2025 21:29 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-001636 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001127602-25-001059 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,105 Underlying: Common Stock · 2,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $49.32 | $98,640.00 |
DisclosureSEC source: 0001127602-25-001059 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 21:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,000 | $10.60 | $21,200.00 |
DisclosureSEC source: 0001127602-25-001059 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2024 Filed Dec 10, 2024 22:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-028977 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2024 Filed Dec 10, 2024 22:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $50.65 | $101,300.00 |
DisclosureSEC source: 0001127602-24-028977 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,071 Read SEC document |
| December 10, 2024 Filed Dec 10, 2024 22:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $50.63 | $268,339.00 |
DisclosureSEC source: 0001127602-24-028977 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,071 Read SEC document |
| December 10, 2024 Filed Dec 10, 2024 22:42 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-028977 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028719 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,071 F3 · kind: Transaction represents shares of PSUs whose performance condition was satisfied but that remain subject to time-based vesting. These PSUs to vest in full December 3, 2025. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,028 | $51.51 | $104,462.28 |
DisclosureSEC source: 0001127602-24-028719 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,071 F2 · kind: Transaction represents withholding of shares to satisfy grantee's tax obligations in connection with vesting PSUs. Read SEC document |
| December 03, 2024 Filed Dec 5, 2024 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028719 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,099 F1 · kind: Transaction represents gross shares of common stock received by grantee upon vesting of Performance Stock Units ("PSUs"). Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-028135 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $50.14 | $100,280.00 |
DisclosureSEC source: 0001127602-24-028135 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,878 Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $50.17 | $265,901.00 |
DisclosureSEC source: 0001127602-24-028135 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,878 Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-028135 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-027240 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,042 | $58.48 | $60,936.16 |
DisclosureSEC source: 0001127602-24-027240 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,878 Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $58.48 | $309,944.00 |
DisclosureSEC source: 0001127602-24-027240 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,920 Read SEC document |
| November 12, 2024 Filed Nov 13, 2024 22:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-027240 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 5,300 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001127602-24-026160 · form4.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,900 Underlying: Common Stock · 5,300 shares Expires 2025-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,000 | $51.93 | $103,860.00 |
DisclosureSEC source: 0001127602-24-026160 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,920 Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 5,300 | $51.90 | $275,070.00 |
DisclosureSEC source: 0001127602-24-026160 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,920 Read SEC document |
| October 30, 2024 Filed Oct 31, 2024 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,300 | $7.96 | $42,188.00 |
DisclosureSEC source: 0001127602-24-026160 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.